


## Evaluation of a novel bench-top stirred-tank bioreactor for process development of autologous T-cell therapies

Michael Delahaye <sup>1</sup>, Henrieta Fraser <sup>1</sup>, Leanne Partington <sup>1</sup>, Sarah Callens <sup>1</sup> & Dave Thomas <sup>2</sup>


<sup>1</sup> Cell and Gene Therapy Catapult, Contact: Mike.delahaye@ct.catapult.org.uk  
<sup>2</sup> Sartorius Stedim Biotech (formerly TAP Biosystems)

### Background and Aim

- Current manufacturing solutions for autologous cell therapies consist of stationary vessels (flasks or bags), requiring a high level of manipulation and costly scale-out throughout the product expansion phase. Agitated vessels, such as stirred-tank reactors (STR) and lateral movement culture systems which are more amenable to scalability, have enhanced control of the culture environment, and provide automation of culture maintenance and analysis.
- Sartorius Stedim Biotech (formerly TAP Biosystems) has been developing a prototype small scale single-use STR from process development activities, and in partnership with the Cell and Gene Therapy Catapult, wished to evaluate performance of the prototype when used in an autologous suspension cell therapy scale-up and scale-out application. The prototype system contained two separate bioreactor stations (denoted, BR1 and BR2) under individual control by the system software, and single-use bioreactor vessels with integrated reagent reservoirs.
- A cell bank of lymphocytes was generated for use within system testing (see Protocols below) and used to evaluate the prototype bioreactor in supporting T-cell expansion and how it compared with both static bags and lateral movement alternatives.



### Protocols




Parameter	Static Bag	Lateral Motion GE Xuri 2L	Prototype Bioreactor
Temp	37°C (AC)	37°C (AC)	37°C (AC)
CO <sub>2</sub>	5% (AC)	5% (AC)	5% (AC)
pH	-	7.0 - 7.6 (NAC)	7.0 - 7.6 (AC)
DO	-	NAC	>50% utilising stirring cascade
Headspace gas (air) flow rate	-	300 mL/min (AC)	75 mL/min (AC)
Agitation	-	500 mL: 15 rpm @ 6° (AC) 1000 mL: 15 rpm @ 8° (AC)	125 mL: 150 rpm (AC) 250 mL: ≤250 rpm (AC)
Mixing Time (assessed by dye injection)	-	500 mL: 42s	125mL: 2s


(AC = Active Control, NAC = Non-Active Control)

- Cell count and viability assessed with Vi-Cell XR, data shown is mean ± 1 S.D., n=3
- Supernatant [Glucose] and [Lactate] quantified via Cubian HT-270, data shown is the mean of duplicate measurements
- Off-line pH measurements were conducted using a Mettler Toledo SevenEasy™ pH meter, data shown is n=1
- The volume of daily samples taken was 2.5% of the vessel working volume
- Expression analysis was conducted using the MACSQuant® Analyser 10 Flow Cytometer, data shown is mean ± 1 S.D., n=3


### Study 1



### Study 2



### Study 3



### Conclusions

- The prototype bioreactor supports T-cell expansion and merits further investigation for optimisation of T-cell expansion processes
- Industry standard, static bag culture, is consistently outperformed by agitated alternatives
- Distribution of nutrients, waste product and pH gradient is improved by agitation, and is achieved more rapidly in the prototype bioreactor
- Efficient mass transfer pivotal to successful proliferation of cell populations
- Exhaustion markers such as KLRG1 and CD57 only detected at low level <5% for all harvested material (data not shown)

### Acknowledgements

This work was co-funded by TAP Biosystems and Innovate UK, the UK's innovation agency (grant number 102163)